Carolyn A. Felix Laboratory
Researchers at the Center for Childhood Cancer Research are currently evaluating the use of antibody drug conjugates and targeted small molecule drugs as treatments for acute myeloid leukemia (AML) in a Phase III clinical trial.
Researchers at the Center for Childhood Cancer Research are using zebrafish models to understand the role of MLL in the normal development of the nascent hematopoietic system from its origins in the embryo.
Studies currently in progress at the Center for Childhood Cancer Research are evaluating the antiviral agent ribavirin as a targeted agent with lower toxicity than conventional therapy to treat MLL-rearranged infant ALL.
Researchers are analyzing clinical samples and medical outcomes data from AML clinical trials to establish possible molecular links between specific AML germline or somatic mutations and disease progression and treatment responsiveness.
Researchers at the CCCR performed chart review for 12 different AEs for pediatric patients enrolled in U.S.-based COG Phase III clinical trials for pediatric acute myeloid leukemia (AML). Results from this analysis showed the current system of AE reporting on cooperative group oncology trials had modest sensitivity and a demonstrable false positive rate.
Studies underway at the Center for Childhood Cancer Research are investigating the role of the DNA cutting enzyme TOP2 in the etiology of both infant leukemias with MLL (KMT2A) gene translocations, as well as chemotherapy-related leukemias with translocations of the MLL gene and other translocations.
Researchers at the Center for Childhood Cancer Research are investigating new immunotherapies using chimeric antigen receptor (CAR)-modified T cells to treat children with relapsed and refractory AML.